PharmaShots | Incisive News in 3 Shots

Subscribe Now

Metastatic Triple-Negative Breast Cancer

Roche's Tecentriq (atezolizumab) + Paclitaxel Fail to Meet the Primary Endpoint in P-III IMpassion131 Study for Patients with Metastatic Triple-Negative Breast Cancer

Roche's Tecentriq (atezolizumab) + Paclitaxel Fail to Meet the Primary Endpoint in P-III IMpassion131 Study for Patients with Meta...

August 7, 2020

Immunomedics' Trodelvy Receives the US FDA's Accelerated Approval for 2L Patients with Metastatic Triple-Negative Breast Cancer (TNBC)

Immunomedics' Trodelvy Receives the US FDA's Accelerated Approval for 2L Patients with Metastatic Triple-Negative Breast Cancer (T...

April 22, 2020

Merck & Co. Reports Results of Keytruda (pembrolizumab) + CT in P-III KEYNOTE-355 Study as 1L Treatment for Metastatic Triple-Negative Breast Cancer

Merck & Co. Reports Results of Keytruda (pembrolizumab) + CT in P-III KEYNOTE-355 Study as 1L Treatment for Metastatic Triple-...

February 12, 2020

Immunomedics Reports the US FDA's Acceptance of BLA for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer

Immunomedics Reports the US FDA's Acceptance of BLA for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer

December 27, 2019

Roche's Tecentriq (atezolizumab) + Abraxane Receive European Commission's Approval for Patients with PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Roche's Tecentriq (atezolizumab) + Abraxane Receive European Commission's Approval for Patients with PD-L1-Positive Metastatic Tri...

August 29, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us